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ABSTRACT
There is increasing concern globally about the enormity 
of the threats posed by antimicrobial resistance (AMR) 
to human, animal, plant and environmental health. A 
proliferation of international, national and institutional 
reports on the problems posed by AMR and the need 
for antibiotic stewardship have galvanised attention 
on the global stage. However, the AMR community 
increasingly laments a lack of action, often identified as 
an ‘implementation gap’. At a policy level, the design of 
internationally salient solutions that are able to address 
AMR’s interconnected biological and social (historical, 
political, economic and cultural) dimensions is not 
straightforward. This multidisciplinary paper responds by 
asking two basic questions: (A) Is a universal approach to 
AMR policy and antibiotic stewardship possible? (B) If yes, 
what hallmarks characterise ‘good’ antibiotic policy? Our 
multistage analysis revealed four central challenges facing 
current international antibiotic policy: metrics, prioritisation, 
implementation and inequality. In response to this 
diagnosis, we propose three hallmarks that can support 
robust international antibiotic policy. Emerging hallmarks 
for good antibiotic policies are: Structural, Equitable and 
Tracked. We describe these hallmarks and propose their 
consideration should aid the design and evaluation of 
international antibiotic policies with maximal benefit at 
both local and international scales.
INTRODUCTION: ANTIMICROBIAL RESISTANCE AS 
A BIOSOCIAL PROBLEM
Since their introduction in the 1930s, anti-
biotics have acquired infrastructural impor-
tance in global health and food produc-
tion.1 However, antibiotic reliance comes 
with a trade- off: using antibiotics accelerates 
the emergence of antimicrobial resistance 
(AMR), which diminishes their future effec-
tiveness. This makes effective antibiotics a 
precious ‘global common- pool resource’,2–6 
which can benefit humanity but will provide 
diminishing benefits if we fail to coordi-
nate plans for preservation (a tragedy of the 
commons).
Over the past decade, rising concern 
about AMR has highlighted the need for 
collective action to protect our antibiotic 
‘commons’.2 7–12 Governmental and non- 
governmental organisations have devoted 
substantial resources to tackling AMR and 
preserving antibiotic effectiveness on national 
and international stages.13 Increasing atten-
tion and funding have been accompanied 
by a proliferation of expert reports and 
policy proposals.14 While these AMR- focused 
initiatives have succeeded in achieving a 
clear international consensus on the need 
for action, many lament a lack of action in 
practice, dubbed an ‘implementation gap’. 
Substantial uncertainties also remain about 
Summary box
 ► The global crisis of antimicrobial resistance has led 
to a proliferation of expert reports and national and 
international antibiotic action plans.
 ► Implementing international antibiotic policy that is 
meaningful in different social, cultural and economic 
contexts continues to prove challenging.
 ► Our multidisciplinary analysis has identified four 
critical challenges of metrics, prioritisation, imple-
mentation and inequality for international antibiotic 
policy- making.
 ► We propose a corresponding SET of basic hall-
marks of good antibiotic policy, which we define as 
Structural, Equitable and Tracked.
 ► Our SET of hallmarks can orientate disciplinary de-
bates and provide a framework for developing robust 
international interventions.
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the effects of different policy interventions, how interna-
tional policies could be enforced globally, and who will 
pay in the long term. The main difficulty with managing 
the antibiotic commons seems to lie in jointly addressing 
the complex biological and social (understood here to 
be historical, political, economic and cultural) dimen-
sions of AMR. Policy formation for the latter dimension 
is particularly challenging because it entails addressing 
different metrics, meanings and challenges in different 
settings.
We propose a new wide- angle approach to AMR- 
focused antibiotic regulation. Two basic questions guide 
our reflective process: (A) Is a universal approach to 
AMR policy and antibiotic stewardship possible? (B) If 
yes, what hallmarks characterise ‘good’ antibiotic policy?
To answer these questions, we have developed an inno-
vative heuristic evaluation framework, which accounts 
both for AMR’s biological and social facets. Our approach 
was informed by the numerous national and interna-
tional reports proposing various principles for antibiotic 
policy- making2 10 11 15–17 and the historical success of the 
3Rs (Reduction, Refinement and Replacement) that 
restructured laboratory animal testing protocols. Devel-
oped as principles of ‘good animal experimentation’ in 
1959, the 3Rs were concrete and aspirational enough to 
trigger a progressive evolution of protocols and dialogue 
in a contested policy arena.18(So et al have proposed 
three Rs for antimicrobial development).19
Applying this approach to AMR and antibiotic policy, 
our collaborative multidisciplinary analysis employed a 
three- stage evidence gathering, evaluation and consul-
tation process (box 1), which consisted of: (1) asking 
selected medical humanities and sciences researchers 
whether they believe antibiotic policies could feasibly 
be guided by a universal set of guiding principles, and 
what they consider those guiding principles could be; 
(2) identifying possible hallmarks of good policy with a 
broad group of stakeholders from academia, medicine, 
animal/plant production, policy and funding bodies at 
an international workshop and (3) refining identified 
hallmarks in light of multidisciplinary feedback.
We believe that the resulting heuristic compass based 
first on the identification of central challenges of anti-
biotic policy- making (metrics, prioritisation, implemen-
tation, inequality) and second on the formulation of a 
corresponding Structural, Equitable and Tracked (SET) 
of hallmarks of good antibiotic policy, which we define 
as SET can orientate disciplinary debates and provide a 
framework for robust international interventions.10 20 21
THE FOUR CENTRAL CHALLENGES OF ANTIBIOTIC REGULATION
Metrics
Despite long- standing regulation attempts, there remains 
substantial uncertainty about basic metrics surrounding 
antibiotic usage and AMR as well as about how to corre-
late measurements in a way that can inform meaningful 
policy formulation at the national and international 
levels.22
How to define resistance?
Since the first warnings about ‘drug fastness’ in micro-
organisms in 1907,23 24 there has been no clear transdis-
ciplinary or international consensus on how to define 
AMR. The constantly evolving nature of AMR, the 
Box 1 Three stage evidence gathering, evaluation and 
consultation process
Stage 1:
Following a 2018 Social Science and antimicrobial resistance 
(AMR) Research Symposium at the British Academy in London,162 a 
correspondence group of fourteen experts from the humanities, social, 
environmental and medical sciences reflected on whether there could 
be universal principles of international antibiotic policy making and 
hallmarks of ‘good’ policy.
Stage 2:
Identified policy challenges and core hallmarks of successful 
intervention informed a preliminary paper, which was circulated 
among correspondents and attendees of a multidisciplinary 2- day 
workshop in London in March 2019.
During presentations, small group breakout sessions, and group 
discussions, participants reflected on the preliminary paper’s four 
identified problem areas for antibiotic regulation: (A) metrics (defining 
and measuring AMR, antibiotic usage and performance indicators for 
interventions); (B) prioritisation (prioritising specific forms of antibiotic 
use over others); (C) implementation (developing and implementing 
interventions that are meaningful in high- income, medium- income 
and low- income settings); (D) inequality (formulating interventions 
that take into account global disparities of wealth, infectious disease 
and AMR burdens and access to antibiotics as well as effective health, 
water, sanitation and hygiene systems).
There was agreement on these interlinked problems but the 
four provisional hallmarks proved more contentious: (1) antibiotic 
policymaking should take into account antibiotics’ infrastructural 
relevance in medicine and food production; (2) should increase the 
microbial resilience of health and food systems to diminish the need 
for antibiotics; (3) be responsive to evolving knowledge regarding AMR 
and (4) relational in its acknowledgement of differing local challenges 
and capacities.
Participants agreed that there was no single solution to AMR but 
felt that hallmarks needed to be integrated and go beyond preserving 
the status quo. Key to more effective policymaking has to be an 
acknowledgement of antibiotics’ primary utility for global health and 
food production, which consists in their ability to reduce mortality 
and morbidity resulting from treatable infections. To preserve this 
utility, the overriding aim of any antibiotic policy must therefore be 
(1) to maximise and maintain access to effective treatments for 
infections, which includes the development of new treatments—while 
(2) reducing the need for antibiotic use by preventing infections, 
reducing antibiotic dependencies in healthcare and food systems, 
and minimising the environmental load of antibiotics and resistant 
bacteria.
Stage 3:
A refined version of new Structural, Equitable, Tracked Hallmarks was 
circulated among correspondents and participants, who were invited 
to be coauthors on the paper.
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introduction of new drugs and the different availability 
and use of antibiotics means that terms like drug sensi-
tive, intermediate resistant or resistant, mean different 
things in different regional contexts. There is also no 
transdisciplinary consensus on whether to define AMR 
according to predefined clinical breakpoints, minimum 
inhibitory concentrations, epidemiological cut- offs, phar-
macokinectic/pharmacodynamic models, the presence 
or absence of resistance- conferring genetic elements or 
clinical impact on patients or animals. Disagreement over 
this latter point is highlighted by the common absence 
of drug- resistant infection as an official cause of death. 
Historically, the lack of consensus over AMR has led to 
differing microbiological and public health definitions 
of AMR with the former measuring incremental changes 
of microbial susceptibility and the latter measuring 
instances of treatment failure at predefined dosages.25–27
Whose methods count?
Internationally, the establishment of WHONET (est. 
1989) and WHO’s Global Antimicrobial Resistance 
Surveillance System (GLASS, est. 2015) marked impor-
tant efforts to standardise AMR reporting in humans 
and make data comparable.28 29 However, coordina-
tion problems remain: testing protocols by influential 
bodies like the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and the US- based Clin-
ical Laboratory Standards Institute (CLSI) occasionally 
diverge. Resulting international monitoring differences 
are exacerbated by issues of access (see problem area 
Inequality).30 EUCAST guidelines and updates are avail-
able free of charge. By contrast, CLSI guidelines and 
updates are often pay for use, which makes it difficult for 
resource poor laboratories to keep protocols up to date 
and feedback local AMR data into international data-
bases.31 In low and middle income countries (LMICs), 
surveillance is often further complicated by lack of access 
to laboratory equipment, service contracts and paywalled 
literature.32 Ensuing disparities in global AMR reporting 
mean that international reports disproportionately reflect 
data from resource- rich settings and a limited number of 
well- studied low- income sentinel sites with international 
healthcare infrastructure investment.33 Resulting inter-
national stewardship and policy guidelines may, however, 
be of limited use in understudied resource- poor settings 
with different AMR ecologies and no access to key anti-
biotics.
What is relevant antibiotic use data for AMR?
Capturing relevant data on antibiotic use to inform 
AMR efforts has its own challenges. Starting in the 
1990s, various high income countries (HICs) began to 
compile antibiotic usage data.34–37 However, data collec-
tion methods continue to vary. In the case of antibiotic 
usage in animals, the World Organisation of Animal 
Health (OIE) has begun to collect data on antibiotic 
sales intended to be used in animals and usage data 
since 2015. However, despite ongoing progress, data gaps 
remain with almost 25% of 182 OIE Member Countries 
not reporting quantitative and most reporting antibiotic 
sales and imports data but no data on use for the fourth 
OIE round of data collection.38 Reporting differences 
are also common among HICs. The EU developed a 
standardised metric to correlate antibiotic sales with the 
volume of animal production (mg/population correc-
tion unit) from 2010 onwards.39 Individual EU countries 
like Britain and Denmark publish not just sales but farm 
usage and prescription data for certain livestock catego-
ries.40 41 By contrast, the US Food and Drug Administra-
tion (FDA) publishes sales data only in broad categories 
of drug class by species but no usage data, which compli-
cates AMR risk assessment.42
Correlating usage and AMR data is even more chal-
lenging. In its 2018–2019 report, the English Surveillance 
Programme for Antimicrobial Utilisation and Resistance 
(ESPAUR) showed a significant reduction in antibiotic 
prescriptions but an increase in antimicrobial- resistant 
infections for the seven priority bacterial pathogens 
reported.43 In 2017 and 2019, longitudinal studies of 
bloodstream infections in Malawi showed a long- term 
reduction of overall infections but a rise of antibiotic 
resistance in remaining infections.33 44 To be useful, 
aggregated metrics of antibiotic usage (including class of 
antibiotic) across infection types need to be contextual-
ised with outcome and population health metrics, such as 
infection, resistance and morbidity/mortality rates.45–47
Understanding what the implications of specific forms 
of antibiotic usage (eg, prophylaxis, therapy, growth 
promotion) in different environments are for AMR and 
health outcomes is similarly crucial for policy formula-
tion. Rising numbers of point prevalence studies and 
whole- genome sequencing are enhancing our knowl-
edge of drivers and variations of AMR over time and in 
different areas across the world.48–51 However, our wider 
understanding of the evolutionary factors underlying 
AMR levels is still fragmentary as is our understanding of 
which stewardship interventions might make how much 
of a difference: in some cases like targeted 1950s anti-
biotic prescription bans at St Bartholomew’s Hospital 
in London52 or Denmark’s 1990s ban of lower- dosed 
avoparcin and tylosin animal growth promoters, reducing 
selection pressure by a specific type of drug usage led to a 
marked reduction, but not a complete disappearance, of 
correlating AMR.53 54 In other cases, antibiotic reductions 
may take years to manifest in terms of reduced AMR—as 
highlighted by the UK’s 2019 ESPAUR report and expe-
riences in Scandinavian countries.43 53 55 Finally, some 
usage reductions may come too late to shift the evolu-
tionary balance back in favour of microbial sensitivity as 
occurred with China banning the use of colistin growth 
promoters in 201656 following a report of the transferable 
mobilisable colistin resistance MCR-1 gene.57 Subsequent 
reports, however, showed that the gene was detectable in 
strain collections from more than 30 countries and was 
already circulating in Escherichia coli in China in the mid 
1980s.58 The lack of uniformly comparable data makes 
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it more difficult to evaluate trade- offs in various policy 
options.
How to develop meaningful key performance indicators?
While uncertainty remains about the degree to which 
interventions will be effective, reducing the overall 
amount of antibiotics used in health and animal and plant 
production systems is a key component of most AMR 
action plans.11 13 59 Over the past two decades, interna-
tional bodies have attempted to decide which antibiotics 
to protect from overuse. Since 2004, WHO, OIE and the 
Food and Agriculture Organization (FAO) have begun 
using the categories of critically important antimicrobials 
(CIAs), highly important antimicrobials and important 
antimicrobials—although differences in the categorisa-
tion of the same drugs for veterinary and medical usages 
can remain.60 61 In 2019, the WHO’s Essential Medicines 
List added the AWaRe categorisation, to meet a need 
to recognise those medicines that should be Accessed as 
first- line narrow- spectrum treatment for particular condi-
tions, and those with higher risks of becoming resistant 
that should be used Watchfully and those that should be 
Reserved for last- line treatment.62 This framework can 
be used as an index—the ratio of Access to Watch and 
Reserve medicines—to compare prescribing practices in 
different contexts, which goes some way to balancing the 
different challenges of improving access and restricting 
excess when setting targets.63 However, measurement of 
antibiotic usage remains a challenge. Although WHO and 
OIE have standardised methodologies to collect country- 
level antimicrobial usage in humans and animals for 
global reporting and consulting companies like IQVIA 
gather and sell additional proprietary data,64 65 more 
granular level detail about antibiotic usage on farms and 
in particular clinical and residential settings is required 
for targeted reduction strategies.66 67
Alongside improved usage data, deciding which 
microbes, resistance genes and AMR reservoirs to 
monitor in medical, animal and plant production, and 
environmental settings is similarly important for the 
formulation of meaningful policy interventions. For 
humans, WHO published a list of priority pathogens to 
monitor and target with antibiotic development efforts in 
2017.68 For animals, the OIE Member Countries agreed 
on harmonised lists for both terrestrial and aquatic 
animals.69 70 However, it remains difficult to prioritise 
which sentinel organisms to survey and where potentially 
important AMR reservoirs are located due to different 
health threats in HICs, MICs and LICs, lacking clinical 
surveillance infrastructure in many LMICs and of envi-
ronmental surveillance in the most countries, regionally 
skewed reporting that often centres on urban clinical 
settings, and limited diagnostic capabilities for non- classic 
pathogens.71 72 Furthermore, particular microbes such as 
Staphylococcus aureus and E. coli may or may not be causing 
disease, and therefore, their measurement without corre-
sponding disease burden data might be misleading.
Discussed in more detail below (see Tracked), one 
recently proposed solution for human health might be 
to integrate AMR and infection burden measurements 
by tracking two priority organisms in bloodstream infec-
tions as part of United Nations (UN) Sustainable Devel-
opment Goal (SDG) 3.d.1. This new AMR- specific SDG 
could help build laboratory capacity in resource- poor 
settings and spur the development of further integrated 
AMR- specific metrics. Another approach might be to 
strengthen point prevalence studies for specific sentinel 
organisms in LMIC settings.73 (Consultations on sentinel 
organisms and sentinel sites are ongoing by GLASS and 
the point prevalence survey).
The described temporal and contextual challenges of 
defining resistance, measuring antibiotic usage in rela-
tion to AMR and concerning which microbes to focus on 
also raise important questions when it comes to defining 
benchmarks or key performance indicators (KPIs) for 
policy initiatives: how far should antibiotic sensitivity 
be restored or preserved for a measure to be consid-
ered successful? Should the performance of a policy be 
linked to its reduction of antibiotic usage or should the 
KPI be demonstrated impact on human health? Should 
success be defined as the stabilisation or decline of AMR 
in specific culturable pathogens? Given the mobility of 
resistance genes and the One Health dimensions, should 
a metric of success be the abundance or prevalence of 
a particular resistance gene in the wider environment, 
determined through quantitative PCR methods74? How 
much time should policies have to achieve their goals?
Prioritisation
Overemphasis on surveillance data itself can serve to 
obscure different regional capabilities, underlying polit-
ical interests and competing needs in animal and human 
medicine.75 In addition to defining meaningful metrics, a 
significant challenge facing international antibiotic regu-
lation is which form of antibiotic use to prioritise in the 
face of time- limited microbial sensitivity to most drugs 
and heterogeneous epidemiological, social, economic 
and material contexts. The challenge of prioritisation 
comprises spatial and temporal components.
Spatial: since the 1940s, regulators have tried to protect 
important antibiotics by restricting their use,76 but this 
path- dependent prioritisation has been enacted differ-
ently across varying local, regional and national settings. 
Antibiotics’ infrastructural importance in global health-
care and food production means that a large number of 
sectors with different needs depend on routine antibi-
otic access.1 In the case of Europe and North America, 
historians have shown that distinct national antibiotic 
usage patterns have become socially entrenched over 
decades.77–81 To this day, antibiotic usage patterns vary 
across Europe and North America despite both regions' 
close economic, political and cultural ties.82 83 Differ-
ences of usage are even more substantial between HICs 
and LMICs with patients in the latter countries often 
depending to a much stronger degree on the efficacy 
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of a limited number of locally available, affordable and 
easily administrable drugs—particularly in areas where 
there is no access to professional healthcare facilities.84–86 
If different countries, sectors and even local healthcare 
facilities87 use different antibiotics for a variety of biolog-
ical and social reasons, whose form of antibiotic use 
should receive priority?
The same problems of spatial prioritisation hold true 
in animal and plant production.34 88 One example of 
spatialised inequality of access are the polymyxin antibi-
otics (eg, colistin, discovered in 1949). After using the 
drugs to treat gram- negative infections in humans, HICs 
greatly reduced use of polymyxins in favour of less toxic 
carbapenems from 1980 onwards.89 Although limited use 
of ‘old’ colistin continued in HICs, their low cost and 
lacking HIC demand for human medicine led to aggres-
sive pharmaceutical marketing and large- scale uptake 
for growth promotion and disease prevention in the 
industrialising animal production of LMICs like China 
and Brazil.88 When rising carbapenem resistance led to a 
resurgence of polymyxin use in human medicine around 
2005, competing animal production and medical priori-
ties meant that global regulators did not raise polymyxins’ 
status to that of CIAs. It was only after the discovery of the 
mcr-1 gene on transferable plasmids in bacterial isolates 
from Chinese pigs that polymyxins were recategorised as 
highest priority CIAs in 2016, received specific restriction 
recommendations from OIE, and were banned from use 
as growth promoters in China and Brazil.57 60 75
Temporal: another challenge of prioritisation regards 
the inevitable temporal conflict between acute health-
care needs and the future- focused dimensions of anti-
biotic stewardship.90 There is a well- evidenced ethical 
dilemma between preserving drugs’ future efficacy and 
using antibiotics to safe- guard vulnerable populations in 
the present. This is highlighted by studies on the rise of 
multidrug- resistant pathogens in itinerant and immuno-
compromised HIC and MIC populations91–94 or of AMR 
proliferation as a result of high levels of antibiotic use 
in prolonged crisis situations like the 2009 H1N1 influ-
enza or the current COVID-19 pandemic.95–98 Similar 
dilemmas have also become apparent in campaigns of 
antimicrobial mass drug administration to prevent child 
stunting,99 100 against onchocerciasis, lymphatic filariasis 
or malaria,101 in the mass administration of azithromycin 
against drivers of childhood mortality in Tanzania, Niger 
and Malawi,102 103 and to prevent scabies and impetigo on 
the Solomon Islands.104
Answers to this temporal dilemma vary and reflect 
the perceived severity of need, cultural preferences for 
specific forms of use, and economic considerations. In 
some cases, the potential longer- term risk to public health 
of antibiotic resistance has been favoured over immediate 
clinical needs.105 However, in the main, present needs 
have overridden future- focused stewardship concerns. 
While there is no reason not to use antibiotics to save 
and improve lives, they have often been used as a ‘quick 
fix’106 to symptomatically control rather than eliminate 
underlying drivers of infection in human, animal health 
and plant production systems. The tendency to see anti-
biotics as ‘quick fixes’ has helped drive AMR and often 
distracted from investment in more sustainable forms of 
infection prevention like effective and affordable health, 
Water, Sanitation and Hygiene (WASH), and Infection 
Prevention Control (IPC) systems (see also Inequality 
below).85 Over- reliance on antibiotics has also been exac-
erbated by industry marketing of, in part, inappropriate 
antibiotic usage and targeted campaigning to under-
mine usage restrictions in high- income and low- income 
settings.34 77 107
Implementation
A third fundamental challenge for antibiotic policy- 
making concerns the formulation of binding interna-
tional agreements that can still be implemented flexibly 
in different settings.17 108 Recent international agree-
ments like the 2016 UN Paris Agreement on climate 
change remain based on the classic so- called Westphalian 
model of sovereign nation- states agreeing on a set of 
measures, which are then independently enacted within 
their borders without control by other actors.7 12 109 110 
There are a number of challenges with this model: global 
trade flows are not easily regulated by nation- level poli-
cies; with few exceptions like the International Health 
Regulations on pandemics, international organisations 
like the WHO cannot enforce health agreements nego-
tiated under their umbrella; the ability of governments 
to implement policies varies.8 20 110 111 Described imple-
mentation problems are exacerbated by the widespread 
absence of basic data and robust metrics (see above) to 
inform international policymaking. For example, while it 
may seem straightforward to define and evaluate policy 
success as reductions of drug usage in HICs, these metrics 
will likely fail in settings without reliable consumption/
usage data and where informal grey market and unreg-
ulated over- the- counter sales account for a large part of 
the antibiotic supply.82 112 113
Using an integrated political, economic, sociolog-
ical, technological, ecological, legislative and industry 
framework, reviews of national action plans proposed 
after the 2015 Global Action Plan on Antimicrobial 
Resistance have warned of continuing gaps in applying 
international concepts of stewardship at the national 
level.114 115 Focusing only on international and not on 
actual local policy alignment can foster the creation 
of ‘paper tiger’ initiatives, which are not enforced—as 
in the case of enacted but not enforced bans of over- 
the- counter antibiotic sales116—or obscure or relabel 
existing practices rather than reform underlying antibi-
otic infrastructures.13 117 118 Follow- up reports by WHO, 
UN and World Bank have proposed solutions including 
international investment in local IPC, antibiotic quality 
assurance and access schemes, AMR surveillance, vacci-
nation, local stewardship champions and contextualised 
policy- making.10 20 21 111 In the case of animal production, 
experts have proposed using AMR monitoring in sentinel 
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pathogens and technical support from HICs as tools to 
incentivise global reductions of antibiotic usage.119 Prom-
ising access to lucrative markets and using transnational 
integration to promote precautionary antibiotic policies 
is an additional tool that was used by the UK in the 1970s, 
Sweden in the 1990s, and is now being considered by the 
EU to reduce antibiotic growth promoter and prophy-
lactic antibiotic use in non- European countries.34 120
However, so far, enactment of proposed measures 
has been fragmentary13 and it remains unclear how 
numerous national and international calls to action with 
complex interlayered principles of action can be trans-
lated into effective change in settings where antibiotic 
access is lacking and AMR is secondary (at best) to other 
health concerns. Looking beyond top- down nationstate 
alignment, by reemphasising municipal and community- 
based health initiatives as well as creating new metrics for 
antibiotic access before prioritising stewardship may be a 
solution. Recent social sciences research suggests the effi-
cacy of adaptive value- driven bottom- up reforms. These 
reforms move from merely sanctioning inappropriate 
antibiotic use to identifying the sociostructural factors 
driving antibiotic use and devising targeted incentives 
for locally tailored shifts to more appropriate antibiotic 
use.121–123 However, it remains unclear whether relying 
on local or even regional solutions will be able to solve 
the global challenge posed by AMR. Calls for behavioural 
change, industry reform and individualised policymaking 
have often been ineffective.34 77
Inequality
One of the most significant challenges facing interna-
tional antibiotic policy and global health frameworks 
more widely are significant levels of inequality between 
and within HICs and LMICs. These inequalities reflect 
historically uneven social and political opportunity as 
well as distribution of economic resources and disease 
burdens. Inequality has large implications for ways prior-
ities are made and implemented in relation to antibi-
otics. Recognition of these inequalities challenges forms 
of policymaking that focus on metrics of drug reduction 
alone (see Metrics and Implementation above) or prior-
itise protection of HIC hospital antibiotics over LMIC 
needs for access to antibiotics and protein production.
The unevenness of social and political opportunities 
affects who can make or demand policies. At the interna-
tional level, the historical dominance of HICs on relevant 
health bodies and many funders’ and high- level meetings’ 
location in HICs has led to a relative absence of the voices 
of some of the most affected LMIC stakeholders.124 There 
is a historically evidenced danger that this dominance of 
HIC voices can drown out LMIC concerns and lead to 
narrow policies centring on HIC concerns.125 126 Despite 
best intentions, motivations for international antibiotic 
policy initiatives must thus be considered uneven when 
framed with a health security lens—who is the ‘we’ in the 
need to act, and who is the ‘us’ being protected1?
Answering these questions is important. In the case of 
drug development, historical priority setting has been 
HIC- centric due to the greater profitability of high- 
income markets (with a particular emphasis on the most 
lucrative US market) and differing regional risk priori-
ties.111 127 In the case of surveillance, antibiotic resistance 
and usage indicators emerge unevenly from particular 
locations, prioritise particular security concerns and 
carry particular interpretations. When shuttling between 
different contexts in which resistance and use might have 
a different significance, these abstracted numeric indica-
tors can foster a contextual disconnect among decision- 
makers.128 The described surveillance disconnect is 
exacerbated by the relative lack of data from LICs and 
rural settings (see Metrics above). The result is a vicious 
circle: lacking access to equipment, current standards and 
scholarly literature means that disease and AMR burdens 
cannot be measured and published,32 which means that 
there are no data with which to build local expert capacity 
or inform international policy, which compounds the 
obscuring of difference between contexts.
Over time, decontextualised international decision 
making can result in policies that prioritise HIC- centric 
stewardship interventions like targeted drug restrictions 
that may prove deleterious in LMICs where infection 
risks are markedly higher and different.111 129 Limited 
data indicate an inverse correlation between countries' 
gross national income and invasive infections caused by 
WHO top- ranked antibiotic- resistant bacteria.71 Where 
resources are stretched thinly across health systems and 
infrastructure, other priorities than stewardship may 
be more pressing for investment. For example, IPC in 
health facilities and availability of effective WASH systems 
are essential. However, in 2017, ca. 785 million people 
worldwide had no access to safe drinking water, two of 
every seven people had no access to sanitation, and 22% 
of LIC health facilities had no water service.130 131 Indeed, 
investment in IPC and WASH is likely to be most effective 
for reducing AMR in many settings as a base on which 
stewardship might then be built.10 20 132 Furthermore, in 
many settings the ability to provide equitable access to 
essential medicines of sufficient quality, including antibi-
otics, remains elusive.10 112
Similar constraints are true for animal health which 
is related to issues such as food safety, food security and 
animal welfare. Many national and international action 
plans invoke enhanced biosecurity facilities, vaccina-
tion or good husbandry practices as a means to avoid 
unnecessary non- human antibiotic use, but they rarely 
set these measures as (funded) priorities contrary to 
raising awareness, developing surveillance or promoting 
responsible and prudent use, or they risk assuming inap-
propriate livestock production and disease management 
approaches in settings where economic and microbiolog-
ical risks are manifestly different.133–135 While arguments 
for wider systems strengthening should not undermine 
statutory antibiotic reform, decontextualised policies 
focusing only on antibiotic stewardship and surveillance 
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risk distracting from the even more important structural 
absence of adequate and situationally appropriate sani-
tary, veterinary and healthcare systems in many parts of 
the world.
HALLMARKS OF GOOD ANTIBIOTIC POLICY
The four biosocial challenges of metrics, prioritisa-
tion, implementation and inequality require a holistic 
response from international antibiotic policy that is ambi-
tious enough to improve the status quo but concrete and 
evocative enough to be an effective guide. Because such 
policies are enacted within a complex ecosystem, a broad 
perspective needs to inform their design and deployment 
to maximise effectiveness and minimise unintended 
consequences. It is this broad heuristic perspective, 
incorporating One Health, spatial, temporal and ethical 
dimensions that underlies the three interlinked SET hall-
marks proposed here (figure 1).
1. Structural: International antibiotic policies should 
recognise and respond to the multiple aspects of glob-
al antibiotic infrastructures.1 Since the 1930s, antibiot-
ics have replaced older, more expensive forms of infec-
tion control in humans, animals and plants and ena-
bled new medical interventions like organ transplants 
and prosthetic joint implants. Global health and food 
production systems rely on the comparatively cheap 
‘work’ performed by antibiotics. Reforming antibiotic 
use cannot be separated from broader reforms of the 
infrastructures that have evolved around them.
Historically, there has been a tendency to make AMR 
manageable by compartmentalising problems and 
blaming individuals for drug overuse instead of the 
underlying social, political and economic factors driv-
ing antibiotic demand and dependencies (see Metrics 
and Prioritisation).34 77 136 137 In HICs, a long- standing 
focus on technical quick fixes and individual behav-
ioural change meant that farmers and patients were 
routinely blamed for overuse without targeting wider 
infrastructural factors or the companies and experts 
supplying antibiotics.106 Bureaucratic divisions also 
meant that the same antibiotics could be subject to 
different regulations on farms and in clinics (see Im-
plementation). The fact that most reforms stopped 
at national borders further fragmented international 
regulation.76 88 136 Since the adoption of One Health 
terminology by WHO and EU antibiotic regulators 
around 2010,138 nearly all international AMR initia-
tives have attempted to overcome described problems 
by integrating polices for drug regulation in human 
medicine, animal production and the environment. 
However, beyond surveillance, One Health was ini-
tially often narrowly applied to mean ‘animals’ rath-
er than the wider environment—perhaps reflecting 
the absence of the UN Environmental Programme 
from the original Tripartite coalition of FAO, OIE and 
WHO. Recent European, Indian and private initia-
tives now explicitly target wastewaters and industrial 
wastes15 134 139 140 but implementing new standards re-
mains challenging. Meanwhile, our scientific under-
standing of the relative effect of antibiotics, metals and 
biocides on environmental AMR burdens and of the 
efficacy of proposed interventions remains fragmen-
tary.74 141 142
Successful antibiotic stewardship cannot be narrow 
and divorced from the social and environmental con-
texts in which use is taking place. More effective inter-
national policy requires the abandonment of regula-
tory silos, as well as the adoption of context- sensitive 
Figure 1 Interlinked hallmarks of successful antibiotic policy- making.
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models. It requires a broad structural approach to 
reforming not only the international antibiotic supply 
chain (drug producers) but also wider contributing 
global and regional consumption patterns (eg, rising 
global demand for protein) as well as associated socio- 
structural factors (eg, fractured health and WASH in-
frastructures, time constraints on diagnosis, profit in-
centives to prescribe or sell drugs) and environmental 
factors (eg, infection burdens, drug residues in water 
systems).
As evidenced by recent successes in HIC animal pro-
duction and health systems, jointly focusing on pre-
venting disease with vaccines and improved welfare, 
updating the design of surveillance, hospital, animal 
housing systems and modifying antibiotic- seeking be-
haviour by patients and animal and plant producers 
can reduce antibiotic dependencies.143–145 However, 
high- income infrastructural starting points cannot be 
taken for granted elsewhere in the globe (see the In-
equality section). To be effective internationally, the 
nature of ‘intervention’ must be less ‘AMR- specific’ 
and instead build up ‘AMR- sensitive’ changes20 which 
support wider UN SDGs including improved WASH, 
nutrition and access to affordable medical and vet-
erinary healthcare.10 20 While we do not discount the 
importance of traditional regulatory tools like actively 
enforced bans of over- the- counter sales, understand-
ing the work that antibiotics perform in non- HIC set-
tings may also lead to an interlayering of old and new 
policy tools such as subsidised assurance and disease 
insurance schemes for farmers phasing out antibiotics, 
access to high- income markets for animal and plant 
products produced without antibiotics, public anti-
biotic production or certified antibiotic distribution 
schemes.20 127 146 147
2. Equitable: To be impactful globally, international 
antibiotic policies must recognise and respond to the 
unevenness in contributions towards and ability to 
tackle AMR while aiming for an equitable future for 
antibiotics regardless of where they are deployed. His-
torically, inequality and the difficulty of uniform poli-
cy implementation across HICs and LMICs have been 
major obstacles for international antibiotic reform 
(see the Inequality and Metrics section).
Because antibiotic effectiveness is a time- limited glob-
al common pool resource and even robust national 
responses offer little protection from the global cir-
culation of AMR genes and organisms, the sustained 
pooling of international resources is an essential pre-
requisite to overcome identified challenges. Similar to 
climate change, some countries have a greater differ-
entiated responsibility to contribute resources to this 
common pool than others.110 For decades, popula-
tions in HICs have had greater access to the antimicro-
bial commons than their counterparts in LMICs. High 
volumes of HIC usage facilitated the historical selec-
tion for and global circulation of resistant genes and 
organisms while HIC companies disproportionately 
profited from early antibiotic sales. HICs’ historical 
contribution to current AMR levels and role in spread-
ing antibiotic dependent infrastructures to other parts 
of the world88 148 entail a moral obligation to bear a 
higher burden when it comes to mitigating resulting 
problems.110 Similarly, recent and projected high lev-
els of antibiotic use and production in MICs create a 
comparable obligation to contribute resources to mit-
igate problems in poorer areas of the world and for 
future generations.48 119 149 150
Whether action is justified on the basis of historical 
usage, collective responsibility, obligations towards 
future generations, or enlightened self- interest, any 
international policy framework will have to include 
long- term financial and political HIC and MIC com-
mitments to support antibiotic sensitive interventions 
in resource- poor communities. In LICs, antibiotic sen-
sitive international support could centre on building 
human and infrastructural capacity by educating and 
employing more medical and veterinary profession-
als,20 enhancing laboratory provision and expanding 
access to effective, affordable, and safe vaccines, an-
tibiotics, and WASH and health systems. From a One 
Health perspective, international policies should also 
promote economically and environmentally sustaina-
ble forms of animal and plant production as well as 
improve the management of waste containing antibi-
otics.
Well- designed structural and equitable international 
antibiotic policies can generate a global win- win.110 
Building LMIC capacity for disease control and pre-
vention and providing equitable access to effective 
treatments via market reforms, subsidies or public re-
search and development127 151 152 will lower both local 
disease burdens and rising international AMR- related 
healthcare costs.10 20 111 127 In the case of animal and 
plant production, equitable policies will recognise that 
to ensure regional food security, targets for a sustain-
able antibiotic- controlled production system can only 
come after an infrastructural groundwork is in place 
to reduce reliance on these substances.119 123
Because of its structural dimensions, the lack of an easy 
target and a dysfunctional commercial research and 
development pipeline for new antibiotics,127 147 AMR 
has so far failed to attract the same degree of resourc-
es that organisations like the Global Vaccine Alliance 
(GAVI) (est. 2000) or the Global Fund (2002) have 
mobilised for individual diseases like HIV/AIDS, tu-
berculosis, malaria or polio. Achieving truly structural 
and equitable global AMR solutions will depend on the 
more effective generation and pooling of investment 
in safe antibiotic access, coordination of country- level 
policy responses and provision of effective WASH, 
IPC and educational resources.127 This role could be 
fulfilled by the existing Tripartite and a One Health 
Global Leadership Group on AMR.153 Another option 
suggested by some authors is creating a new dedicat-
ed international AMR body or pooled fund similar to 
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GAVI.8 Ultimately, the structural challenges posed by 
AMR exceed the capabilities of any one nation. Over-
coming the significant levels of inequality that have 
hampered previous responses will depend on inten-
sifying international collaboration, equitably pooling 
resources and knowledge, and openly addressing the 
global disparities driving infectious disease burdens 
and the resulting need for antibiotics.
3. Tracked: Progress towards structural and equitable 
antibiotic policies has to be tracked to ensure ongoing 
effectiveness of interventions, promote integration of 
international efforts and motivate sustained commit-
ment of donors and funding recipients. While a reg-
ular independent international stocktake could help 
ensure that policy interventions remain coordinated, 
equitable and up to date,12 the metrics informing glob-
al decision making need to be reviewed and carefully 
chosen.128 To avoid reifying existing inequalities and 
HIC biosecurity concerns (see the Metrics section), 
tracked policies should be based on and promote sys-
tems of contextual data gathering that are: multifacto-
rial in their combination of existing and new metrics; 
integrated in their pooling of knowledge from differ-
ent One Health and regional contexts; and empower-
ing by conferring agency to local communities.
Multifactorial
Achieving effective tracked interventions requires a 
unifying global set of multifactorial metrics. To enable 
the rigorous evaluation of policies, multifactorial 
metrics need to simultaneously take into account antibi-
otic access, AMR and stewardship, but avoid rewarding 
short- termist gaming such as relabelling disease defi-
nitions, disincentivising healthcare- seeking behaviour 
and decontextualising surveillance (see the Inequality 
section).128 154 Standardised terminology and transparent 
AMR and drug usage surveillance are essential prereq-
uisites for the design of meaningful international inter-
ventions. However, focusing too narrowly on reducing 
drug usage and misuse will not curb microbial threats 
(see Implementation section). Vice versa, focusing only 
on providing drugs without supporting additional means 
to reduce disease burdens will achieve little in the long 
term. Since 2018, several ways have been proposed to 
integrate AMR into the UN SDG framework. The most 
recent proposal is to ‘reduce the percentage of blood-
stream infections due to selected antimicrobial resistant 
organisms’ and has been recommended to go forward 
to the UN Statistical Commission for inclusion in SDG 3 
(Good Health and Well- being).73 This is one promising 
way to address stewardship without detracting from the 
goals of antibiotic access and disease prevention (see the 
Metrics section). There is, however, an additional need 
for new multifactorial metrics that also encompass AMR’s 
environmental and animal health dimensions as well as 
local access to drugs, WASH, vaccines and coselection for 
resistance by other antimicrobial substances. The new 
monitoring and evaluation framework proposed by FAO, 
OIE and WHO in 2019 is an important step in this direc-
tion.155
Integrated
In addition to drawing on multifactorial metrics, policy 
tracking should aim to integrate metrics across domains: 
taking into account the legacies of pre- existing inter-
ventions, improving knowledge integration across One 
Health sectors and incorporating knowledge generated 
in other geographical and social contexts. Enhancing 
the integration of international knowledge gathering will 
strengthen regionally nuanced decision making. Since 
the 1940s, successive generations of regulators have 
tried to manage the antibiotic commons by focusing on 
one form of intervention like ‘rational’ antibiotic use, 
reducing antibiotic use via statutory bans or non- statutory 
incentives and replacing antibiotics (eg, using metals in 
animal feeds). However, lack of cross- sectoral and inter-
national integration meant that benefits were often 
short- lived and had little effect on global drug usage or 
AMR.34 76 137 156 157 Regulatory silos at the national and 
international level have also repeatedly impeded the 
transmission of knowledge generated in one sector to 
other sectors—something that is exacerbated by the fact 
that animal health, medical and environmental regula-
tors rarely interact on equal terms.158–160 In the case of 
AMR, the result was a lack of long- term strategic plan-
ning, a fragmentation of international policies and basic 
metrics (see the Metrics section)—and a tendency to 
reinvent the wheel—for example, the almost decennial 
recurrence of official warnings about post- antibiotic 
futures and ‘rational’ antibiotic use campaigns.77 161 
Developing equitable structural policy frameworks thus 
not only depends on evaluating progress with multifac-
torial metrics but also on actively integrating knowledge 
throughout the One Health domains, leveraging existing 
national and regional policy frameworks and retaining 
institutional knowledge.
Empowering
Developing multifactorial and integrated metrics will 
achieve little if global AMR and usage data continues 
to be generated and made available unevenly. Equitably 
boosting laboratory and data analysis capacity is a prereq-
uisite for strengthening the ability of those on the front 
lines of human, animal and plant health to devise their 
own solutions and generate accurate data for the global 
community. For example, in 2010, the Danish Yellow Card 
Initiative required farmers and veterinarians to track and 
record on farm antibiotic use. The initiative comple-
mented low- granularity sales data and helped respective 
communities better understand what they were doing 
and grow support for stewardship efforts.54 In LMICs, 
enhancing national and local capacity to generate data 
can have similar effects. Being able to produce and wield 
robust surveillance data can increase the political weight 
of LMIC concerns at the international level. OIE, WHO 
and the UK Fleming Fund are already strengthening 
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LIC usage and AMR surveillance capacity. However, 
organisations still lack sufficient resources to sustainably 
support laboratories and countries to enable them to 
publish accurate country- level data.29 New multifacto-
rial and integrated metrics are also needed to produce 
data that is meaningful in settings without formal health 
and veterinary care systems. In the long term, reducing 
reliance on decontextualised data gathering like trav-
eller surveillance and restructuring reporting formats to 
better reflect varying circumstances (see the Inequality 
section) will significantly enhance the evidence base for 
truly structural and equitable international antibiotic 
policy- making.
CONCLUSION
The past eight decades have seen antibiotic policy- makers 
struggle to overcome problematic metrics, narrow prior-
itisations, implementation deficits and global inequali-
ties. The need for integrated architectures that act across 
existing silos to push evidence into action on AMR is 
being met through United Nations mandated mecha-
nisms.10 To move beyond previous impasses, interna-
tional policy will have to take seriously the infrastructural 
dimensions of antibiotic use, provide equitable solutions 
for communities across the globe and develop new forms 
of tracking progress that are multifactorial, integrated 
and empowering for the communities employing them.
Policies that take into account antibiotics’ SET have 
the greatest potential to sustainably adapt the way the 
global antibiotic commons are managed and accessed. As 
highlighted in our ideal- type example of multifactorial 
metrics and equitable capacity building in global food 
production (figure 2), SET policies have the potential to 
foster win- win situations for HIC and LMIC participants 
alike.
If the ultimate goal of antibiotic policy is to reduce 
mortality and morbidity resulting from treatable infec-
tions, then we need to adapt our food and health systems 
to provide optimal access to effective antibiotic interven-
tions when they are needed—and simultaneously reduce 
the need for these interventions. This dual approach 
requires polices that not only focus on ‘quick fixes’106 
for existing systems and behavioural modifications at the 
level of the individual. Instead, policies should consis-
tently seek to adapt the wider physical and cultural infra-
structures antibiotics are embedded in.
AMR is not a problem to be solved but a phenomenon 
to be continuously managed. Individual policies may not 
address all identified problem areas or integrate each of 
our three intervention hallmarks. However, we believe 
that our multidisciplinary SET of hallmarks can serve as 
a compass to critically evaluate and improve antibiotic 
policy in the present and for decades to come.
Author affiliations
1School of History, University College Dublin, Dublin, Ireland
2Oxford Martin School, University of Oxford, Oxford, UK
3Department of Public Health and Policy/ Institute of Infection and Global Health, 
University of Liverpool, Liverpool, UK
4School of Social and Political Sciences, Faculty of Arts and Social Sciences, The 
University of Sydney, Sydney, New South Wales, Australia
5Princess Maha Chakri Sirindhorn Anthropology Center, Bangkok, Thailand
6Antimicrobial Resistance and Veterinary Products Department, World Organisation 
for Animal Health, Paris, Île- de- France, France
Figure 2 An ideal- type set of interventions for international food production. Ideal- type example of how using reflective 
policy- making in accordance with SET hallmarks could inform the design of equitable trade arrangements to: satisfy high 
income country demand for affordable sustainably produced protein; fulfil low income country calls for structural healthcare 
and surveillance capacity building and market access; encourage value driven. One health stewardship with multifactorial 
metrics integrating data on animal health with low- cost environmental sentinel monitoring for antimicrobial residues as a proxy 
for regional antimicrobial use (AMU). AMR, antimicrobial resistance; SET, Structural, Equitable and Tracked.
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from 
Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091 11
BMJ Global Health
7Irisso, Paris- Dauphine University, PSL, INRAE, Paris, Île- de- France, France
8Center for Disease Dynamics Economics and Policy, Washington, DC, USA
9Department of Infectious Disease, Imperial College London, London, UK
10Institute for Health and Society, Dept. of Community Medicine and Global Health, 
University of Oslo, Oslo, Norway
11Geography, College of Life and Environmental Sciences and Wellcome Centre for 
Cultures and Environments of Health, University of Exeter, Exeter, UK
12Global Strategy Lab, Dahdaleh Institute for Global Health Research, Faculty of 
Health and Osgoode Hall Law School, York University, Toronto, Ontario, Canada
13Institute for Science, Innovation and Society, School of Anthropology and Museum 
Ethnography, University of Oxford, Oxford, UK
14Infectious Diseases Research Collaboration, Kampala, Central Region, Uganda
15School of Law, Social Innovation on Drug Program, Boston University, Boston, 
Massachusetts, USA
16Department of Global Health and Social Medicine, Harvard Medical School, 
Boston, Massachusetts, USA
17Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, 
Liverpool, UK
18Pollution, UK Centre for Ecology & Hydrology, Wallingford, UK
19Department of International Health, Johns Hopkins University Bloomberg School 
of Public Health, Baltimore, Maryland, USA
20Innovation + Design Enabling Access (IDEA) Initiative, ReAct - Action on Antibiotic 
Resistance, Baltimore, Maryland, USA
21Faculty of Social Sciences, Mahidol University, Salaya, Nakhon Pathom, Thailand
22Global Coordination and Partnerships, AMR Division, World Health Organisation, 
Geneva, Switzerland
23Global Strategy Lab, York University, Toronto, Ontario, Canada
24Department of Global Health and Development, London School of Hygiene & 
Tropical Medicine, London, UK
Twitter Claas Kirchhelle @Kirchhelle, Alex Broom @BroomAlex, Isabel Frost 
@IsabelFrost19, Steven J Hoffman @shoffmania, Kevin Outterson @koutterson, 
Adam P Roberts @anthroamr and Andrew C Singer @OxonAndrew
Acknowledgements We are grateful to all correspondents and participants of 
the 2019 workshop for sharing their insights and expertise. The workshop and 
activity for this manuscript was supported by the Antimicrobials in Society (AMIS) 
programme (https:// anti micr obia lsin society. org/). The authors would like to thank 
Charlotte Kirchhelle for her help in preparing the figures of this article.
Contributors CK and CC conceived the concept and cowrote this article with 
contributions from PA, AB, KC, JPF, NF, IF, CG, SH, SJH, JL, SN, KO, SHP, SR, APR, 
SRVK, ACS, ADS, LS, ET. CC acquired funding for the workshop and the articles.
Funding AMIS is funded by The Antimicrobial Resistance Cross Council Initiative 
supported by the seven research councils in partnership with other funders. 
The lead funders are the Economic and Social Research Council (ESRC) with the 
Department of Health and the Arts and Humanities Research Council (AHRC). 
Kirchhelle’s work was supported by a Wellcome Trust University Award at University 
College Dublin and the Oxford Martin School. Fortané was supported by INRAE 
(ANR-18- CE03-001), Frost by CDDEP, Nayiga by ESRC, Taylor by the UK Fleming 
Fund. APR would like to acknowledge funding from the AMR Cross- Council 
Initiative through a grant from the Medical Research Council, a Council of UK 
Research and Innovation (Grant Number; MR/S004793/1)
Disclaimer The views expressed in this article are those of the authors and do not 
necessarily reflect those of CIHR, the Government of Canada, or WHO.
Competing interests SH is Scientific Director of CIHR’s Institute of Population 
and Public Health and CIHR’s Scientific Co- Lead for Antimicrobial Resistance. He 
is Director of the WHO Collaborating Centre on Global Governance of Antimicrobial 
Resistance. KO in principal investigator of CARB- X, a project at Boston University 
(my employer), funded by three governments (US, UK and Germany) and two 
charitable foundations (Wellcome Trust and the Bill & Melinda Gates Foundation). 
CARB- X is a non- profit, making grants for preclinical antibacterial research. I 
do not view this as a conflict, but disclose in an abundance of caution. APR is 
the co- ordinator of the JPIAMR funded Network NEAR- AMR. ADS reports grants 
from ReAct- Action on Antibiotic Resistance and from Open Society Foundation 
during the conduct of the study. He served as Co- Convener of the UN Interagency 
Coordination Group on Antimicrobial Resistance (2018–2019), as a member of 
the Expert Commission on Addressing the Livestock Contribution to the Antibiotic 
Resistance Crisis (2016–2017), as a commissioned author to the UK Commission 
on AMR on 'A Framework for Costing the Lowering of Antimicrobial Use in Food 
Animal Production' (2016), as Head of the Secretariat of the Antibiotic Resistance 
Coalition, and as a Member of the Working Group on Antibiotic Resistance for the 
President’s Council of Advisors on Science and Technology (2013–2014).
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement There are no data in this work.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Claas Kirchhelle http:// orcid. org/ 0000- 0003- 0910- 8133
Isabel Frost http:// orcid. org/ 0000- 0002- 0095- 0845
Steven J Hoffman http:// orcid. org/ 0000- 0002- 2064- 3711
Adam P Roberts http:// orcid. org/ 0000- 0002- 0760- 3088
Clare I R Chandler http:// orcid. org/ 0000- 0001- 6499- 7522
REFERENCES
 1 Chandler CIR, Hutchinson E, Hutchison C. Addressing antimicrobial 
resistance through social theory. An Anthropologically oriented 
report. London: London School of Hygiene & Tropical Medicine, 
2016.
 2 Hoffman SJ, Caleo GM, Daulaire N, et al. Strategies for achieving 
global collective action on antimicrobial resistance. Bull World 
Health Organ 2015;93:867–76.
 3 Hollis A, Maybarduk P. Antibiotic resistance is a tragedy of the 
commons that necessitates global cooperation. J Law Med Ethics 
2015;43 Suppl 3:33–7.
 4 Cars O, Högberg LD, Murray M, et al. Meeting the challenge of 
antibiotic resistance. BMJ 2008;337:a1438.
 5 Laxminarayan R, Malani A. Extending the cure: policy responses to 
the growing threat of antibiotic resistance: Earthscan, 2007.
 6 Outterson K. The vanishing public domain: antibiotic resistance, 
pharmaceutical innovation and intellectual property law. Lawreview 
2005;67:67.
 7 Hoffman SJ, Outterson K. Introduction: what will it take to address 
the global threat of antibiotic resistance? J Law Med Ethics 
2015;43 Suppl 3:6–11.
 8 Rogers Van Katwyk S, Weldon I, Giubilini A, et al. Making use 
of existing international legal mechanisms to manage the global 
antimicrobial commons: identifying legal Hooks and institutional 
mandates. Health Care Anal 2020;105. doi:10.1007/s10728-020-
00393-y. [Epub ahead of print: 31 Mar 2020].
 9 Wernli D, Haustein T, Conly J, et al. A call for action: the application 
of the International health regulations to the global threat of 
antimicrobial resistance. PLoS Med 2011;8:e1001022.
 10 IACG. No time to wait: securing the future from drug- resistant 
infections. Report to the Secretar- General of the United nations. 
New York: Interagency Coordination Group on Antimicrobial 
Resistance, 2019.
 11 WHO/OIE/FAO. Global action plan on antimicrobial resistance. 
Geneva: World Health Organisation, 2015.
 12 Van Katwyk SR, Balasegaram M, Boriello P, et al. A roadmap for 
sustainably governing the global antimicrobial commons. Lancet 
2019;394:1788–9.
 13 Rogers Van Katwyk S, Grimshaw JM, Nkangu M, et al. 
Government policy interventions to reduce human antimicrobial 
use: a systematic review and evidence MAP. PLoS Med 
2019;16:e1002819.
 14 Kirchhelle C, Broom A, Chandler C, et al. The Informational 
Deluge - A Review of 72 years of antibiotic evaluation, surveillance, 
regulation, and calls to actionin preparation.
 15 Tackling antimicrobial resistance 2019–2024. The UK’s five- year 
national action plan. London Her Majesty’s Government, 2019.
 16 WHO. Who global principles for the containment of antimicrobial 
resistance in animals intended for food: report of a who 
consultation with the participation of the food and agriculture 
organization of the United nations and the office international des 
Epizooties, Geneva, Switzerland 5-9 June 2000. World Health 
Organization, 2000.
 17 Hoffman SJ, Outterson K, Røttingen J- A, et al. An international 
legal framework to address antimicrobial resistance: SciELO public 
health, 2015.
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from 
12 Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091
BMJ Global Health
 18 Kirk RGW. Recovering The Principles of Humane Experimental 
Technique: The 3Rs and the Human Essence of Animal Research. 
Sci Technol Human Values 2018;43:622–48.
 19 So AD, Ruiz- Esparza Q, Gupta N, et al. 3Rs for innovating 
novel antibiotics: sharing resources, risks, and rewards. BMJ 
2012;344:e1782–4.
 20 Bank W. Pulling together to beat superbugs. knowledge and 
Implementaiton gaps in addressing antimicrobial resistance. 
Washington DC: World Bank, 2019.
 21 WHO. Turning plans into action for antimicrobial resistance (AMR). 
Working paper 2.0: implementation and coordination. Geneva: 
World Health Organization, 2019.
 22 Dar OA, Hasan R, Schlundt J, et al. Exploring the evidence base 
for national and regional policy interventions to combat resistance. 
Lancet 2016;387:285–95.
 23 Summers WC. Microbial drug resistance: a historical perspective. 
Bacterial Resistance to Antimicrobials 2008;2:1–9.
 24 Gradmann C. Magic bullets and moving targets: antibiotic 
resistance and experimental chemotherapy, 1900-1940. Dynamis 
2001;31:305–21.
 25 Fortané N, Dispositif- Frontière LSC. La triple ontologie des 
bactéries résistantes d’origine animale. Revue d'Anthropologie des 
Connaissances 2015;9:265–90.
 26 Gradmann C. Sensitive matters: the world health organisation 
and antibiotic resistance testing, 1945-1975. Soc His Med 
2013;26:555–74.
 27 Drlica K, Perlin DS, Resistance A. Understanding and responding to 
an emerging crisis. Upper Saddle River: Pearson Education, 2011.
 28 WHO. WHONET software platform. Geneva: World Health 
Organisation.
 29 WHO. Global antimicrobial resistance surveillance system (glass) 
report: early implementation 2017-2018. Geneva: WHO, 2019.
 30 van der Bij AK, van Dijk K, Muilwijk J, et al. Clinical breakpoint 
changes and their impact on surveillance of antimicrobial 
resistance in Escherichia coli causing bacteraemia. Clin Microbiol 
Infect 2012;18:E466–72.
 31 Kassim A, Omuse G, Premji Z, et al. Comparison of clinical 
laboratory Standards Institute and European Committee on 
antimicrobial susceptibility testing guidelines for the interpretation 
of antibiotic susceptibility at a university teaching hospital in 
Nairobi, Kenya: a cross- sectional study. Ann Clin Microbiol 
Antimicrob 2016;15:21.
 32 Saha S, Saha S, Saha SK. Global science: barriers in Bangladesh. 
Elife 2018;7:e41926.
 33 Musicha P, Cornick JE, Bar- Zeev N, et al. Trends in antimicrobial 
resistance in bloodstream infection isolates at a large urban 
hospital in Malawi (1998-2016): a surveillance study. Lancet Infect 
Dis 2017;17:1042–52.
 34 Kirchhelle C. Pyrrhic progress: antibiotics in Anglo- American food 
production (1949-2018). New Brunswick: Rutgers University Press, 
2020.
 35 Hammerum AM, Heuer OE, Emborg H- D, et al. Danish integrated 
antimicrobial resistance monitoring and research program. Emerg 
Infect Dis 2007;13:1633–9.
 36 Mölstad S, Löfmark S, Carlin K, et al. Lessons learnt during 20 
years of the Swedish strategic programme against antibiotic 
resistance. Bull World Health Organ 2017;95:764–73.
 37 Tamura Y. The Japanese veterinary antimicrobial resistance 
monitoring system (JVARM). OIE international standards on 
Antimicrobial Resistance, 2003: 206–10.
 38 OIE. OIE annual report on antimicrobial agents intended for use in 
animals. better understanding of the global situation. third annual 
report. Paris: World Organisation for Animal Health (OIE), 2018.
 39 EMA. Trends in the sales of veterinary antimicrobal agents in 
nine European countries. reporting period: 2005-2009. Brussels: 
European Medicines Agency, 2011.
 40 VMD. Uk veterinary antibiotic resistance and sales surveillance 
report. UK- VARSS 2018. UK- VARSS new Haw veterinary medicines 
Directorate, 2019.
 41 Statens Serum Institut, NF Institute. DANMAP 2018 - Use of 
antimicrobial agents and occurrence of antimicrobial resistance 
in bacteria from food animals, food and humans in Denmark. 
Copenhagen: Statens Serum Institut/ National Food Institute, 
2019.
 42 FDA. 2018 summary report on antimicrobials sold or distributed 
for use in food- producing animals. Washington: Food and Drugs 
Administration, 2019.
 43 English Surveillance Programme for Antimicrobial Utilisation and 
Resistance (ESPAUR). Report 2018-2019. London: Public Health 
England, 2019.
 44 Iroh Tam P- Y, Musicha P, Kawaza K, et al. Emerging resistance to 
empiric antimicrobial regimens for pediatric bloodstream infections 
in Malawi (1998-2017). Clin Infect Dis 2019;69:61–8.
 45 Schnall J, Rajkhowa A, Ikuta K, et al. Surveillance and monitoring 
of antimicrobial resistance: limitations and lessons from the gram 
project. BMC Med 2019;17:176.
 46 Aarestrup FM. Monitoring of antimicrobial resistance among food 
animals: principles and limitations. J Vet Med B Infect Dis Vet 
Public Health 2004;51:380–8.
 47 Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic 
consumption 2000 to 2010: an analysis of national pharmaceutical 
sales data. Lancet Infect Dis 2014;14:742–50.
 48 Van Boeckel TP, Pires J, Silvester R, et al. Global trends in 
antimicrobial resistance in animals in low- and middle- income 
countries. Science 2019;365:eaaw1944.
 49 Giulieri SG, Tong SYC, Williamson DA. Using genomics to 
understand meticillin- and vancomycin- resistant Staphylococcus 
aureus infections. Microb Genom 2020;6:mgen000324.
 50 Baker S, Thomson N, Weill F- X, et al. Genomic insights into 
the emergence and spread of antimicrobial- resistant bacterial 
pathogens. Science 2018;360:733–8.
 51 Bennett RJ, Baker KS. Looking backward to move forward: the 
utility of sequencing historical bacterial genomes. J Clin Microbiol 
2019;57.
 52 Barber M, Dutton AA, Beard MA, et al. Reversal of antibiotic 
resistance in hospital staphylococcal infection. Br Med J 
1960;1:11–17.
 53 Kahn LH. One health and the politics of antimicrobial resistance 
Baltimore. Johns Hopkins University Press, 2016.
 54 FAO. Tackling antimicrobial use and resistance in pig production. 
lessons learned in Denmark. Rome: Food and Agricultural 
Organisation/ Ministry of Environment and Food of Denmark, 2019.
 55 Sørum M, Johnsen PJ, Aasnes B, et al. Prevalence, persistence, 
and molecular characterization of glycopeptide- resistant 
enterococci in Norwegian poultry and poultry farmers 3 to 
8 years after the ban on avoparcin. Appl Environ Microbiol 
2006;72:516–21.
 56 Walsh TR, Wu Y. China bans colistin as a feed additive for animals. 
Lancet Infect Dis 2016;16:1102–3.
 57 Liu Y- Y, Wang Y, Walsh TR, et al. Emergence of plasmid- mediated 
colistin resistance mechanism MCR-1 in animals and human 
beings in China: a microbiological and molecular biological study. 
Lancet Infect Dis 2016;16:161–8.
 58 Shen Z, Wang Y, Shen Y, et al. Early emergence of mcr-1 in 
Escherichia coli from food- producing animals. Lancet Infect Dis 
2016;16:293.
 59 WHO. Library of national action plans. Geneva: World Health 
Organisation, 2020.
 60 OIE. OIE list of antimicrobial agents of veterinary importance: world 
organisation for animal health, 2019.
 61 FAO/OIE/WHO. Second joint FAO/OIE/WHO expert workshop 
on non- human antimicrobial usage and antimicrobial resistance: 
management options. Oslo, Norway. Geneva: World Health 
Organisation, 2004.
 62 WHO. Executive summary. The selection and use of essential 
medicines 2019. Report of the 22nd who expert Committee on the 
selection and use of essential medicines. Geneva: World Health 
Organisation, 2019.
 63 Sharland M, Pulcini C, Harbarth S, et al. Classifying antibiotics in 
the who essential medicines list for optimal use- be aware. Lancet 
Infect Dis 2018;18:18–20.
 64 Góchez D, Raicek M, Pinto Ferreira J, et al. OIE annual report on 
antimicrobial agents intended for use in animals: methods used. 
Front Vet Sci 2019;6:317.
 65 WHO. Who methodology for a global programme on surveillance 
of antimicrobial consumption. Geneva: World Health Organisation, 
2016.
 66 Queenan K, Chandler CIR, Goodman C. A review of methods 
and metrics for studying human and livestock antibiotic use at the 
granular level. London LSHTM, 2017.
 67 Queenan K, Chandler CIR, Goodman C. Meeting report: metrics 
and methods for assessing antibiotic use at the granular level in 
humans and livestock in LMICs. London: LSHTM, 2017.
 68 WHO. Global priority list of antibiotic- resistant bacteria to guide 
research, discovery, and development of new antibiotics. Geneva: 
World Health Organization, 2017.
 69 OIE. Development and harmonisation of national antimicrobial 
resistance surveillance and monitoring programmes for aquatic 
animals. aquatic animal health code. Paris: World Organisation For 
Animal Health, 2012.
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from 
Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091 13
BMJ Global Health
 70 OIE. Harmonisation of national antimicrobial resistance surveillance 
and monitoring programmes. Terrestial animal health code. Paris: 
World Organisation for Animal health, 2018.
 71 Savoldi A, Carrara E, Gladstone BP, et al. Gross national income 
and antibiotic resistance in invasive isolates: analysis of the top- 
ranked antibiotic- resistant bacteria on the 2017 who priority list. J 
Antimicrob Chemother 2019;74:3619–25.
 72 Pitzer VE, Meiring J, Martineau FP, et al. The invisible burden: 
diagnosing and Combatting typhoid fever in Asia and Africa. Clin 
Infect Dis 2019;69:S395–401.
 73 So A, Sharma P. Tracking antimicrobial resistance in the 
sustainable development goals, 2019. Available: http:// sdg. iisd. org/ 
commentary/ guest- articles/ tracking- antimicrobial- resistance- in- 
the- sustainable- development- goals/
 74 Singer AC, Shaw H, Rhodes V, et al. Review of antimicrobial 
resistance in the environment and its relevance to environmental 
regulators. Front Microbiol 2016;7:7.
 75 WHO. Critically important antimicrobials for human medicine - 5th 
review. Geneva: WHO, 2017.
 76 Podolsky SH. The evolving response to antibiotic resistance 
(1945–2018). Palgrave Commun 2018;4.
 77 Podolsky SH. The antibiotic era. reform, resistance and the pursuit 
of a rational therapeutics. Baltimore: Johns Hopkins Press, 2015.
 78 Gradmann C. Re- Inventing infectious disease: antibiotic resistance 
and drug development at the Bayer company 1945-80. Med Hist 
2016;60:155–80.
 79 Schröter HG. Zwischen tradition und Fortschritt. AUS Der 
Geschichte Der Pharmabereiche von Bayer, Hoechst und Schering 
von 1935-1975. Frankfurter Historische Abhandlungen 2005;43.
 80 Lie AK, Standards P. Producing Standards, producing the Nordic 
region: antibiotic susceptibility testing, from 1950-1970. Sci 
Context 2014;27:215–48.
 81 Hobaek B, Lie AK. Less Is More: Norwegian Drug Regulation, 
Antibiotic Policy, and the "Need Clause". Milbank Q 
2019;97:762–95.
 82 WHO. Who report on surveillance of antibiotic consumption. early 
implementation 2016-2018. Geneva: WHO, 2018.
 83 ECDC. Antimicrobial consumption in the EU/EEA. annual 
epidemiological report for 2018. Brussels: European Centre for 
Disease Control, 2019.
 84 Krockow EM, Tarrant C. The International dimensions of 
antimicrobial resistance: contextual factors shape distinct ethical 
challenges in South Africa, Sri Lanka and the United Kingdom. 
Bioethics 2019;33:756–65.
 85 Kirchhelle C, Dyson ZA, Dougan G. A Biohistorical perspective 
of typhoid and antimicrobial resistance. Clin Infect Dis 
2019;69:S388–94.
 86 Dyson ZA, Klemm EJ, Palmer S, et al. Antibiotic resistance and 
typhoid. Clin Infect Dis 2019;68:S165–70.
 87 Huang SS, Labus BJ, Samuel MC, et al. Antibiotic resistance 
patterns of bacterial isolates from blood in San Francisco County, 
California, 1996-1999. Emerg Infect Dis 2002;8:195–201.
 88 Kirchhelle C. Pharming animals: a global history of antibiotics in 
food production (1935–2017, 2018: 96.
 89 Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival 
of polymyxins for the management of multidrug- resistant gram- 
negative bacterial infections. Clin Infect Dis 2005;40:1333–41.
 90 Littmann J, Viens AM. The ethical significance of antimicrobial 
resistance. Public Health Ethics 2015;8:phv025–24.
 91 McMillen CW, Tuberculosis D, Global History A. To the present. 
New Haven and London: Yale University Press, 2015: 1900.
 92 Neville K, Bromberg A, Bromberg R, et al. The third epidemic--
multidrug- resistant tuberculosis. Chest 1994;105:45–8.
 93 Young DM, Harris HW, Charlebois ED, et al. An epidemic 
of methicillin- resistant Staphylococcus aureus soft tissue 
infections among medically underserved patients. Arch Surg 
2004;139:947–53.
 94 Doron A, Broom A. The spectre of Superbugs: waste, structural 
violence and antimicrobial resistance in India. Worldwide Waste: 
Journal of Interdisciplinary Studies 2019;2.
 95 AAo S, Hindiyeh M, Sabateen AA. Embedding quality improvement 
through a learning collaborative to reduce and sustain hospital- 
acquired infections in the West bank. AMR Control, 2017: 96–8.
 96 Davies M, Stockton B. Unseen enemy: doctors in Gaza. Bureau of 
Investigative Journalism, 2018.
 97 Singer AC, Colizza V, Schmitt H, et al. Assessing the ecotoxicologic 
hazards of a pandemic influenza medical response. Environ Health 
Perspect 2011;119:1084–90.
 98 Rawson TM, Moore LSP, Castro- Sanchez E, et al. COVID-19 
and the potential long- term impact on antimicrobial resistance. J 
Antimicrob Chemother 2020;75:1681–4.
 99 Podolsky SH. Historical perspective on the rise and fall and 
rise of antibiotics and human weight gain. Ann Intern Med 
2017;166:133–8.
 100 Millar M. Inequality and antibiotic resistance: a contractualist 
perspective. Bioethics 2019;33:749–55.
 101 Poirot E, Skarbinski J, Sinclair D, et al. Mass drug administration for 
malaria. Cochrane Database Syst Rev 2013;44.
 102 Bogoch II, Utzinger J, Lo NC, et al. Antibacterial mass drug 
administration for child mortality reduction: opportunities, 
concerns, and possible next steps. PLoS Negl Trop Dis 
2019;13:e0007315.
 103 Keenan JD, Arzika AM, Maliki R, et al. Longer- Term assessment of 
azithromycin for reducing childhood mortality in Africa. N Engl J 
Med 2019;380:2207–14.
 104 Romani L, Marks M, Sokana O, et al. Efficacy of mass drug 
administration with ivermectin for control of scabies and impetigo, 
with coadministration of azithromycin: a single- arm community 
intervention trial. Lancet Infect Dis 2019;19:510–8.
 105 Rid A, Littmann J, Buyx A. Evaluating the risks of public health 
programs: rational antibiotic use and antimicrobial resistance. 
Bioethics 2019;33:734–48.
 106 Denyer Willis L, Chandler C. Quick fix for care, productivity, hygiene 
and inequality: reframing the entrenched problem of antibiotic 
overuse. BMJ Glob Health 2019;4:e001590.
 107 Pearson M, Chandler C. Knowing antmicrobial resistance in 
practice: a multi- country qualitative study with human and animal 
healthcare professionals. Glob Health Action 2019;12:1599560.
 108 Rochford C, Sridhar D, Woods N, et al. Global governance of 
antimicrobial resistance. The Lancet 2018;391:1976–8.
 109 UN. Paris agreement. New York: United Nations, 2016.
 110 Rogers Van Katwyk S, Giubilini A, Kirchhelle C, et al. Exploring 
models for an international legal agreement on the global 
antimicrobial commons: lessons from climate agreements. Health 
Care Anal 2020;387. doi:10.1007/s10728-019-00389-3. [Epub 
ahead of print: 21 Jan 2020].
 111 Clift C. Review of progress on antimicrobial resistance: background 
and analysis. London: Chatham House: The Royal Institute of 
International Affairs, 2019.
 112 Ozawa S, Evans DR, Bessias S, et al. Prevalence and estimated 
economic burden of substandard and Falsified medicines in low- 
and middle- income countries: a systematic review and meta- 
analysis. JAMA Netw Open 2018;1:e181662.
 113 Morgan DJ, Okeke IN, Laxminarayan R, et al. Non- Prescription 
antimicrobial use worldwide: a systematic review. Lancet Infect Dis 
2011;11:692–701.
 114 Ahmad R, Zhu NJ, Leather AJM, et al. Strengthening strategic 
management approaches to address antimicrobial resistance 
in global human health: a scoping review. BMJ Glob Health 
2019;4:e001730.
 115 Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance 
in low- income and middle- income countries. BMJ Glob Health 
2019;4:e002104.
 116 Pokharel S, Adhikari B. Antimicrobial resistance and over the 
counter use of drugs in Nepal. J Glob Health 2020;10:010360.
 117 FAO/OIE/WHO. Monitoring global progress for addressing 
antimicrobial resistance (AMR). analysis report of the second round 
of results of AMR country self- assessment survey. Geneva: FAO/ 
OIE/ WHO, 2018.
 118 Goutard FL, Bordier M, Calba C, et al. Antimicrobial policy 
interventions in food animal production in South East Asia. BMJ 
2017;358:j3544–41.
 119 So AD, Shah TA, Roach S, et al. An integrated systems approach 
is needed to ensure the sustainability of antibiotic effectiveness 
for both humans and animals. J Law Med Ethics 2015;43 Suppl 
3:38–45.
 120 EU. MEPs back plans to halt spread of drug resistance from 
animals to humans. Brussels: European Parliament, 2018.
 121 Broom A, Kenny K, Kirby E, et al. Improvisation, therapeutic 
brokerage and antibiotic (mis)use in India: a qualitative interview 
study of Hyderabadi physicians and pharmacists. Crit Public Health 
2020;30:16–27.
 122 Broom J, Broom A, Kirby E. Context- Sensitive antibiotic 
optimization: a qualitative interviews study of a remote Australian 
hospital setting. J Hosp Infect 2018;100:265–9.
 123 Hinchliffe S, Butcher A, Rahman MM. The AMR problem: 
demanding economies, biological margins, and co- producing 
alternative strategies. Palgrave Commun 2018;4.
 124 Figuié M. Towards a global governance of risks: international health 
organisations and the surveillance of emerging infectious diseases. 
J Risk Res 2014;17:469–83.
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from 
14 Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091
BMJ Global Health
 125 Manton J, Gorsky M. Health planning in 1960s Africa: international 
health organisations and the post- colonial state. Med Hist 
2018;62:425–48.
 126 Packard R. A history of global health: interventions into the lives of 
other peoples. Baltimore: Johns Hopkins Press, 2016.
 127 Singer AC, Kirchhelle C, Roberts AP. (Inter)nationalising the 
antibiotic research and development pipeline. Lancet Infect Dis 
2020;20:e54–62.
 128 Adams V. Metrics: what counts in global health. Duke University 
Press, 2016.
 129 Bhutta ZA, Sommerfeld J, Lassi ZS, et al. Global burden, 
distribution, and interventions for infectious diseases of poverty. 
Infect Dis Poverty 2014;3:21.
 130 WHO. Who Factsheet: drinking water. Geneva: World Health 
Organisation, 2019.
 131 WHO. Who Factsheet: sanitation. Geneva: World Health 
Organisation, 2019.
 132 OIE, WHO FAO. Technical brief on water, sanitation, hygiene 
and wastewater management to prevent infections and reduce 
the spread of AMR. Rome, Paris, Geneva: Food and Agriculture 
Organization, World Organisation for Animal Health, World Health 
Organization, 2020.
 133 FAO. The Fao action plan on antimicrobial resistance 2016-2020. 
Rome: FAO, 2016.
 134 EU. A European one health action plan against antimicrobial 
resistance (AMR). Brussels: European Union, 2017.
 135 OIE. The OIE strategy on AMR and the prudent use of antibiotics. 
Paris: World Organisation for Animal Health/ OIE, 2016.
 136 Podolsky SH, Bud R, Gradmann C, et al. History teaches us that 
confronting antibiotic resistance requires stronger global collective 
action. J Law Med Ethics 2015;43 Suppl 3:27–32.
 137 Glover RE, Dangoor M, Mays N. Educating patients or blaming 
them? public education campaigns on antibiotic resistance. BMJ 
Opinion 2019.
 138 Commission E. Com (2011) 748 final communication from the 
Commission to the European Parliament and Council – action plan 
against the rising threats from antimicrobial resistance Brussels. 
European Commission, 2011.
 139 Indian Ministry of Environment FaCC. GSR 44 (E) Draft Notification. 
The Gazette of India 2020 (No. 41 Part II - Section 3 - Sub- section 
(i)), 2020: 1–11.
 140 IFPMA. AMR Industry Alliance - 2020 Progress Report, 2020.
 141 Gov.UK. Uk five year antimicrobial resistance strategy and action 
plan 2013-2018, 2013.
 142 FAO/WHO. Joint FAO/WHO meeting in collaboration with OIE on 
foodborne antimicrobial resistance: role of the environment, crops 
and biocides. microbiological risk assessment series. Rome, 2019.
 143 EMA. Sales of veterinary antimicrobial agents in 31 European 
countries in 2017. trends from 2010 to 2017 ninth ESVAC report. 
Brussels: European Medicines Agency, 2019.
 144 Nuffield Trust. Antibiotic prescribing UK. London; 2019.
 145 FDA. Summary report on antimicrobials sold or distributed for 
use in food- producing animals. Washington DC: Food and Drugs 
Administration, 2018.
 146 Wellcome Trust News. Five pioneering ways to stop superbugs. 
23.05.2019 ED. London, 2019.
 147 Roope LSJ, Smith RD, Pouwels KB, et al. The challenge of 
antimicrobial resistance: what economics can contribute. Science 
2019;364:eaau4679.
 148 Silbergeld EK. Chickenizing Farms & Food. How Industrial Meat 
Production Endangers Workers, Animals, and Consumers. 
Baltimore: Johns Hopkins University Press, 2016.
 149 Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and 
geographic convergence in antibiotic consumption between 2000 
and 2015. Proc Natl Acad Sci U S A 2018;115:E3463–70.
 150 Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in 
antimicrobial use in food animals. Proc Natl Acad Sci U S A 
2015;112:5649–54.
 151 Outterson K, Powers JH, Daniel GW, et al. Repairing the broken 
market for antibiotic innovation. Health Aff 2015;34:277–85.
 152 Outterson K. New business models for sustainable antibiotics. 
London Chatham House - Royal Institute of International Affairs, 
2014.
 153 IACG. No time to wait: securing the future from drug- resistant 
infections. New York Interagency coordination group on 
antimicrobial resistance, 2019.
 154 Reddy SG. Economics’ Biggest Success Story Is a Cautionary Tale. 
Foreign Policy, 2019.
 155 FAO/OIE/WHO. Monitoring and evaluation of the global action 
plan on antimicrobial resistance. framework and recommended 
indicators. Rome/ Paris/ Geneva: Food and Agricultural 
Organisation/ World Organisation for Animal Health/ World Health 
Organisation, 2019.
 156 Gradmann C. From lighthouse to hothouse: Hospital hygiene, 
antibiotics and the evolution of infectious disease, 1950-1990. Hist 
Philos Life Sci 2017;40:8.
 157 Kirchhelle C, Song S. Swann song: antibiotic regulation in British 
livestock production (1953-2006). Bull Hist Med 2018;92:317–50.
 158 Kirchhelle C. Between Bacteriology and Toxicology - Agricultural 
Antibiotics and US Risk Regulation. In: Creager ANH, Gaudilliere 
J- P, eds. Risk on the table. New York: Berghahn, 2021.
 159 Jerolmack C. Who's worried about turkeys? How 'organisational 
silos' impede zoonotic disease surveillance. Sociol Health Illn 
2013;35:200–12.
 160 Chien Y- J. How did international agencies perceive the avian 
influenza problem? The adoption and manufacture of the 
'One World, One Health' framework. Sociol Health Illn 
2013;35:213–26.
 161 Podolsky SH, Lie AK. Futures and their uses: antibiotics and 
therapeutic revolutions. therapeutic revolutions: pharmaceuticals 
and social change in the twentieth century. Chicago: University of 
Chicago Press, 2016: 18–42.
 162 Antimicrobials in Society [AMIS]. Social Science and AMR 
Research Symposium - British Academy, London 2018. Available: 
https:// anti micr obia lsin society. org/ events/ social- science- and- amr- 
research- symposium/
 o
n
 Septem
ber 29, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from 
